Autologous CAR-T-cell production is costly and has a long production cycle, and patient lymphocytes are few and poorly functional; UCAR-T cells from healthy donors appear to overcome these limitations, but can induce GVHD and their persistence is disrupted by the host immune system.25 Multiplex genomic CRISPR/Cas9-edited UCAR-T cells exhibit potent anti-tumor activity in vitro and in animal models, similar to non-gene-edited CAR-T cells.136 CRISPR/Cas9-designed universal CD19/CD22 CAR-T cells exhibit a controlled safety profile and outstanding hemocytosis-free activity. This evidence concerns the gene CD19 and neoplasm.